Alveus: Best-in-class opportunity in obesity

Alveus believes it could have best-in-class obesity therapies for both the maintenance setting and amylin class within its pipeline, differentiating on tolerability and infrequent dosing benefits. A syndicate of blue-chip investors topped up the Philadelphia-based biotech’s nearly $200 million series A round last week to give the company runway to generate data that aims to demonstrate those benefits in the clinic.

According to CEO Raj Kannan — who has held the CEO post at biotechs such as Novabridge Biosciences (NASDAQ:NBP, formerly I-Mab) and Aerie Pharmaceuticals Inc. — Alveus Therapeutics Inc. was created not simply to develop an obesity therapeutic that generates the highest degree of weight loss. Instead, the company is targeting three areas where it thinks there is still a large unmet need. ...